7:09 AM
 | 
Jun 04, 2018
 |  BC Extra  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated, as did Sofinnova Partners,...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >